Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection

Hepatology

Volumn 28, Issue 1, 1998, Pages 179-191

  Tennant, Bud C ^a   Baldwin, Betty H ^a   Graham, Lou Ann ^a   Ascenzi, Mary A ^a   Hornbuckle, William E ^a   Rowland, Peter H ^a,e   Tochkov, Ilia A ^a   Yeager, Amy E ^a   Erb, Hollis N ^a   Colacino, Joseph M ^b   Lopez, Carlos ^b   Engelhardt, Jeffery A ^b   Bowsher, Ronald R ^b   Richardson, Frank C ^b,f   Lewis, William ^c   Cote, Paul J ^d   Korba, Brent E ^d   Gerin, John L ^d  

^a Department of Obstetrics Gynecology   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Histopath Consulting   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FIALURIDINE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIGEN; TRIACYLGLYCEROL LIPASE; VIRUS ANTIGEN; VIRUS DNA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOT HYBRIDIZATION; FEMALE; FOOD INTAKE; HEPATITIS B; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER BIOPSY; LIVER FAILURE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TOXICITY; WOODCHUCK;

ANIMALS; ANOREXIA; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; CARRIER STATE; DNA, VIRAL; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; LIVER; MARMOTA; MUSCLES; SLEEP STAGES; TIME FACTORS; VIRUS REPLICATION;

EID: 17344366353     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280124     Document Type: Article

References (8)

1. McLaren C, Chen MS, Barbhaiya RH, Buroker RA, Oleson FB. Preclinical investigations of FIAU, an anti-herpes agent. In: Kono R, ed. Herpes Viruses and Viral Chemotherapy. New York: Elsevier Science Publishers, 1985:57-61.
2. Schinazi RF, Fox JJ, Watanabe KA, Nahmias AJ. Activities of 1-(2-deoxy2-fluoro-β-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. Antimicrob Agents Chemother 1986;29:77-84.
3. Korba BE, Gerin JL. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 1992;19:55-70.
4. Staschke KA, Colacino JM, Mabry TE, Jones CD. The in vitro antihepatitis B virus activity of FIAU [l-(2′-deoxy-2′-fluoro-l-β-Darabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res 1994;23:45-61.
5. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
6. Stevenson W, Gaffey M, Ishitani M, McCullough C, Dickson R, Caldwell S, Lobo P, et al. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proc 1995;27:1219-1221.
7. Wilt A, Williams R, Pierce R. Report of an FDA Task Force. Fialuridine: Hepatic and Pancreatic Toxicity. Washington, DC: Food and Drug Administration, November 12,1993:1-91.
8. Manning FJ, Swartz M, eds. Review of the Fialuridine (FIAU) Clinical Trials. Institute of Medicine. Washington, DC: National Academy Press, 1995;1-269